Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Intranasal Administration of Niclosamide (UNI91103) in Adults With Asymptomatic or Mild COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is male or female aged ≥45 and \<80 years~* Subject is tested to confirm infection with SARS-CoV-2 on a sample taken within 3 days before randomization~* Subject is either without symptoms or has 1 or more of the following symptoms: Stuffy or runny nose, Sore throat, Loss of taste, Loss of smell, Headache.~None of the symptoms should have been present \>5 days.~Exclusion Criteria:~* Subject has an underlying condition that may interfere with intranasal administration of the IMP (e.g., chronic ulcers in the nose).~* Subject has symptoms suggesting engagement of the lower respiratory tract or a systemic engagement~* Subject has an active or acute infection other than SARS-CoV-2~* Subject has another member of the same household recruited to this study

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- UNI91103 intranasal spray 1% (Type: EXPERIMENTAL): UNI91103 intranasal spray 1%, BID, 10 consecutive days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo intranasal spray, BID, 10 consecutive days

Based on this trial design, predict the completion outcome and termination type (if applicable).